Gritstone Oncology, Inc., a Delaware corporation (the “Issuer”).
Item 1(b) | Address of Issuer’s Principal Executive Offices: |
5858 Horton Street, Suite 210
Emeryville, California 94608
Item 2(a). | Name of Person Filing: |
This statement is filed by: (i) The Column Group II, LP, a Delaware limited partnership (“TCG II LP”), (ii) The Column Group II GP, LP, a Delaware limited partnership (“TCG II GP”) and (iii) Peter Svennilson and David V. Goeddel (collectively referred to as the “Managing Partners”). Mr. Svennilson and Mr. Goeddel are the Managing Partners of TCG II GP. Each of the Managing Partners, TCG II LP and TCG II GP are sometimes hereinafter referred to individually as a “Reporting Person” and, collectively, as the “Reporting Persons.”
The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions ofRule 13d-1(k) of the Securities Exchange Act.
Item 2(b). | Address of Principal Business Office or, if none, Residence: |
The address of the principal business office of TCG II LP and TCG II GP, and the business address of each of the Managing Partners, is 1700 Owens Street, Suite 500, San Francisco, California 94158.
See Row 4 of the cover page for each Reporting Person.
Item 2(d). | Title of Class of Securities: |
Common stock, par value $0.0001 per share
39868T105
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.